OFFERING AUSTRALIANS OFFERING AUSTRALIANS A
A CHOICE
CHOICE for staying up-to-date with their COVID-19 vaccinations † for staying up-to-date with their COVID-19 vaccinations for staying up-to-date with their COVID-19 vaccinations † †
As a trusted COVID-19 vaccine provider , you are perfectly placed to address the
As As a a trusted concerns COVID-19 of vaccine
vaccine vaccine cautious
provider provider or hesitant
, you , you are Australians perfectly are perfectly placed placed by offering to address to address them a the the choice of concerns vaccine
of of vaccine to continue cautious to keep or hesitant or hesitant them safe Australians . by offering by offering them them a choice a choice of of vaccine to to continue to to keep keep them them safe safe . .
SARS-CoV-2 rS ( NVX-CoV2373 ) SARS-CoV-2 rS ( NVX-CoV2373 )
AUSTRALIANS AUSTRALIANS HAVE HAVE MORE MORE CHOICE CHOICE OF OF VACCINE AUSTRALIANS HAVE MORE CHOICE OF VACCINE
Australians are are able able to to choose NUVAXOVID , a protein-based adjuvant vaccine developed with with an an Australians are able to choose NUVAXOVID 1 , 2 .
, a protein-based adjuvant vaccine developed with an established vaccine technology 1 , 2 . established vaccine technology 1 , 2 .
ATAGI a 2023 ( 1 ) all at ATAGI
ATAGI increased recommends
recommends risk of a severe 2023
a 2023 COVID-19
COVID-19 COVID-19 booster
booster , or dose
dose for ( 1
for ) all
( 1 adults
) all adults 65yrs
65yrs + and
+ ( and 2 ) all
( adults
2 ) all adults 18-64yrs
18-64yrs at at increased last increased risk of severe risk of COVID-19 severe COVID-19 , or a disability , or with significant complex health needs ; if their last COVID-19 vaccine dose or a confirmed infection was 6 months ago or longer 3 . s 6 months ago or longer 3 . last s 6 months ago or longer 3 . All adults aged 18-64 years without risk factors for COVID-19 should also consider 2023 booster dose if
All All adults their aged last aged COVID-19 18-64 18-64 years years vaccine without without dose risk or risk factors factors for COVID-19 for COVID-19 should should also also consider consider a 2023 a 2023 booster booster dose if dose if their last their COVID-19 last longer COVID-19
, vaccine and regardless vaccine dose or dose of confirmed the or number infection of prior dose ( whichever is the most recent ) was 6 months ago or longer , and longer regardless assessment , and regardless of the with number their of the immunisation number of prior of doses prior provider
dose received 3 . , based on an individual risk benefit assessment with their assessment immunisation with their provider immunisation 3 . provider 3 .
Traditional protein-based One formulation No reconstitution Refrigerator
Traditional protein-based One formulation No reconstitution Refrigerator adjuvant vaccine 1 , 2 and dosage 1 needed 1 stable 1 adjuvant vaccine 1 , 2 and dosage 1 needed 1 stable 1
Every eligible Australian deserves a choice to Every eligible Australian deserves a choice to be protected from COVID-19 with NUVAXOVID
Every be protected eligible from Australian COVID-19 deserves with NUVAXOVID a choice to be protected from COVID-19 with NUVAXOVID
Please refer to the ATAGI statement for the full 2023 updated booster recommendation at https :// www . health . gov . au / news / atagi-2023-booster-advice Please refer to the ATAGI statement for the full 2023 updated booster recommendation at https :// www . health . gov . au / news / atagi-2023-booster-advice
Please refer to the ATAGI statement for the full 2023 updated booster recommendation at https :// www . health . gov . au / news / atagi-2023-booster-advice PBS information : This product is not listed on the NIP or the PBS
PBS information : This product is not listed on the NIP or the PBS
Please review full Product Information before prescribing at www . biocelect . com / products Please review full Product Information before prescribing at www . biocelect . com / products
THIS VACCINE IS SUBJECT TO PBS ADDITIONAL information MONITORING : IN This AUSTRALIA product THIS WILL is ALLOW not listed QUICK IDENTIFICATION on the NIP OF NEW or SAFETY the PBS INFORMATION . THIS VACCINE HEALTHCARE IS SUBJECT PROFESSIONALS TO ADDITIONAL ARE MONITORING ASKED REPORT IN AUSTRALIA ANY SUSPECTED THIS WILL ADVERSE ALLOW QUICK EVENTS IDENTIFICATION WWW . TGAGOVAU OF NEW / REPORTING-PROBLEMS SAFETY INFORMATION ..
HEALTHCARE PROFESSIONALS ARE ASKED TO REPORT ANY SUSPECTED ADVERSE EVENTS AT WWW . TGAGOVAU / REPORTING-PROBLEMS . MINIMUM PRODUCT INFORMATION : NUVAXOVID ( SARS-COV-2 RS [ NVX-COV2373 ]) Suspension for Injection Minimum Product Information . INDICATION : NUVAXOVID has provisional
MINIMUM Please approval PRODUCT review as full an INFORMATION Product active immunisation Information : NUVAXOVID before to prevent ( prescribing SARS-COV-2 coronavirus at RS www [ disease NVX-COV2373 . biocelect 2019 ( COVID-19 ]) . com Suspension / products ) caused for Injection by SARS-CoV-2 Minimum individuals Product Information 12 years of . age INDICATION and older : . NUVAXOVID The use of Nuvaxovid has provisional should be in approval as an active immunisation to prevent coronavirus CONTRAINDICATIONS disease 2019 ( COVID-19 Hypersensitivity ) caused by to SARS-CoV-2 the active in substance individuals or 12 to years any of the age excipients and older . The in NUVAXOVID use of Nuvaxovid . SPECIAL should WARNINGS be in AND
PRECAUTIONS THIS VACCINE Events IS of SUBJECT anaphylaxis TO CONTRAINDICATIONS ADDITIONAL have been reported MONITORING and Hypersensitivity close IN observation AUSTRALIA to the for THIS 15 active minutes WILL substance ALLOW is recommended or QUICK to any IDENTIFICATION following of the excipients vaccination OF . NEW A NUVAXOVID second SAFETY dose . INFORMATION SPECIAL should not WARNINGS be . given to AND those who PRECAUTIONS HEALTHCARE Events of anaphylaxis PROFESSIONALS have been ARE reported ASKED and TO close REPORT observation ANY SUSPECTED for 15 minutes ADVERSE is recommended EVENTS following AT WWW vaccination . TGAGOVAU . A / second REPORTING-PROBLEMS dose should not be . given to those who few days after vaccination and have primarily occurred within 14 days . Individuals are instructed to seek immediate medical attention if they develop symptoms indicative of myocarditis or few days after vaccination and have primarily occurred within 14 days . Individuals are instructed to seek immediate medical attention if they develop symptoms indicative of myocarditis or
MINIMUM PRODUCT INFORMATION : NUVAXOVID ( SARS-COV-2 RS [ NVX-COV2373 ]) Suspension for Injection Minimum Product Information . INDICATION : NUVAXOVID has nausea and vomiting , abdominal pain , dizziness or syncope , oedema , and cough . For further details , please refer to the relevant clinical guidelines de-veloped by the Australian Technical nausea
provisional and Advisory vomiting
approval Group , abdominal on
as Immunisation
an active pain , immunisation dizziness . Anxiety-related or syncope
to prevent reactions , oedema
coronavirus , , including and cough vasovagal
disease . For further
2019 reactions details
( COVID-19 (, syncope please
) caused refer ), hyperventilation to
by the
SARS-CoV-2 relevant , or clinical stress
in individuals guidelines related reactions
12 de-veloped
years may
of age occur by the
and as Australian
older a psychogenic
. The Technical
use response
of Nuvaxovid vaccination Group should Immunisation . be Postpone in accordance vaccination . Anxiety-related with in official individuals reactions recommendations with , including acute severe vasovagal . CONTRAINDICATIONS febrile reactions illness or ( syncope acute infection :), Hypersensitivity hyperventilation . Vaccination , to or should the stress active be related given substance reactions with caution or may to in any occur individuals of as the a psychogenic excipients receiving anticoagulant in response NUVAXOVID to therapy . to
Advisory
vaccination SPECIAL . Postpone WARNINGS vaccination AND PRECAUTIONS in individuals with : Events acute of severe anaphylaxis febrile illness have or been acute reported infection and . Vaccination close observation should be for given 15 minutes with caution is recommended in individuals receiving following anticoagulant vaccination therapy . A second dose lower should in not immunosuppressed be given to those individuals who experience . Individuals anaphylaxis may not be to fully the first protected dose . There until 7 is days an increased after their risk second of myocarditis dose . A protective and pericarditis response may in males not be and induced females in following all vaccine vaccination in INTERACTIONS immunosuppressed . These conditions Concomitant individuals can de-velop administration . Individuals within just may of a NUVAXOVID not few be days fully after with protected vaccination other until vaccines 7 and days has have after not primarily their been second studied occurred dose . ADVERSE . within A protective EFFECTS 14 days response . Individuals Local - may Injection are not instructed be site induced tenderness to in seek all , pain vaccine immediate , redness recipients medical and . swelling .
recipients . lower INTERACTIONS attention Systemic if they Concomitant - Headache develop administration symptoms , nausea / vomiting indicative of NUVAXOVID , myalgia of myocarditis , arthralgia with other , or fatigue pericarditis vaccines , malaise has such , not pyrexia as been ( acute , chills studied and , . ADVERSE persisting pain in extremity EFFECTS ) chest pain . Local This , shortness is - not Injection a full of site breath list tenderness and or for palpitations more , pain details , redness following , refer and to vaccination PI swelling . DOSAGE . . AND Systemic Non-specific METHOD - Headache symptoms OF , ADMINISTRATION nausea of / vomiting myocarditis , NUVAXOVID myalgia and , arthralgia pericarditis is for intramuscular , fatigue also include , malaise injection fatigue , pyrexia only , nausea , chills . Primary , and Series pain vomiting in : Two extremity , doses abdominal . of This 0.5 is mL pain not each , dizziness a full is recommended list and or syncope for more 3 , weeks oedema details apart , , refer and . Booster to cough PI . DOSAGE Dose . For : further A single AND details , booster
METHOD dose please OF ADMINISTRATION of refer 0.5 mL to may the be relevant administered NUVAXOVID clinical is approximately for guidelines intramuscular de-veloped 6 months injection after by only the completion . Primary
Australian of Series a Technical primary : Two doses series
Advisory in of individuals 0.5 Group mL each on 18 is years Immunisation recommended of age and . Anxiety-related 3 older weeks . STORAGE apart . Booster : reactions Store unopened Dose
, including : A single vaccine booster vasovagal
between 2 ° C dose of 0.5 -8 ° mL C , protected may be administered from light . Do approximately not freeze . For 6 more months details after refer completion to PI . of a primary series in individuals 18 years of age and older . STORAGE : Store unopened vaccine between 2 ° C reactions ( syncope ), hyperventilation , or stress related reactions may occur as a psychogenic response to vaccination . Postpone vaccination in individuals with acute severe -8 ° C , protected from light . Do not freeze . For more details refer to PI . febrile ATAGI illness : Australian or acute Technical infection Advisory . Vaccination Group should on Immunisation be given . with NIP : Nat caution in individuals receiving anticoagulant therapy or those with thrombocytopenia or any coagulation ATAGI disorder : Australian † To be ( such considered Technical as haemophilia up Advisory to date ). Group Limited with COVID-19 on data Immunisation vaccination available . NIP for , : you Nat immunocompromised must have had all the doses individuals recommended and pregnant for your women age and . health Efficacy needs may be lower in immunosuppressed individuals . † To Individuals be considered may up not to date be fully with protected COVID-19 vaccination until 7 days , you after must their have second had all dose the doses . A protective recommended response for your may age not and be health induced needs in all vaccine recipients . INTERACTIONS : Concomitant administration of NUVAXOVID with other vaccines has not been studied . ADVERSE EFFECTS : Local - Injection site tenderness , pain , redness and swelling . Systemic - Headache ,
References : References nausea 1 . Nuvaxovid /: vomiting Australian , myalgia , Approved arthralgia Product , fatigue Information , malaise , . pyrexia 2022 . 2 ., Pulendran chills , and B pain , et al in . Nat extremity Rev Drug . This Discov is . not 2021 a ; 20 full ( 6 ): list 454 and – 475 for . 3 . https more :// details www . health , refer . gov to . au PI ./ news DOSAGE / atagi-2023-booster-advice
AND METHOD OF 1 . Nuvaxovid ADMINISTRATION Australian Approved : NUVAXOVID Product is for Information intramuscular . 2022 . 2 injection . Pulendran only B ,. et Primary al . Nat Rev Series Drug : Two Discov doses . 2021 of ; 20 0.5 ( 6 ): mL 454 each – 475 . is 3 . recommended https :// www . health 3 weeks . gov . au / apart news /. atagi-2023-booster-advice
Booster Dose : A single booster dose April of 0.52023 mL | may COM-AU-COV-2300010 be administered | approximately BC0062 _ Nvx _ AU 6 months after completion of a primary series in individuals 18 years of age and older . STORAGE : Store unopened vaccine April between 2023 © Novavax | COM-AU-COV-2300010 2 ° C -8, Inc ° C ,. protected ( 2023 ). | from BC0062 light _ Nvx . Do _ AU not freeze . For more details refer to PI . © Novavax , Inc . ( 2023 ).
ATAGI Suite : Australian
502 , Level Technical
5 , 139 Macquarie Advisory
Street Group
, Sydney on Immunisation
NSW 2000 , Australia . NIP : National Immunisation Program . PI : prescribing information . PBS : Pharmaceutical Benefits Scheme
Suite 502 , Level 5 , 5 Wynn , 139 Macquarie Williams House Street , 47 Sydney Hereford NSW Street 2000 , Christchurch Australia 8013 , New Zealand .
† To be considered up to date with COVID-19 vaccination , you must have had all the doses recommended for your age and health needs Level 5 , Wynn www . Williams biocelect House . com , 47 Hereford Street , Christchurch 8013 , New Zealand . www . biocelect . com References : 1 . Nuvaxovid Australian Approved Product Information . 2022 . 2 . Pulendran B , et al . Nat Rev Drug Discov . 2021 ; 20 ( 6 ): 454 – 475 . 3 . https :// www . health . gov . au / news / atagi-2023-booster-advice
April 2023 | COM-AU-COV-2300010 | BC0062 _ Nvx _ AU © Novavax , Inc . ( 2023 ). Suite 502 , Level 5 , 139 Macquarie Street , Sydney NSW 2000 , Australia Level 5 , Wynn Williams House , 47 Hereford Street , Christchurch 8013 , New Zealand .